<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04713072</url>
  </required_header>
  <id_info>
    <org_study_id>ABY-035-202</org_study_id>
    <nct_id>NCT04713072</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Clinical Trial in Patients With Active Psoriatic Arthritis to Investigate Efficacy, Tolerability, Safety, Pharmacokinetics and Immunogenicity of ABY-035</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affibody</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affibody</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, prospective, multicenter, randomized, double-blind, placebo-controlled,&#xD;
      dosefinding trial in parallel-groups with primary endpoint at Week 16 (visit V9) to&#xD;
      investigate the efficacy, tolerability, safety, pharmacokinetics and immunogenicity of&#xD;
      ABY-035 in adult patients with PsA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ABY-035 drug molecule is a selective inhibitor of interleukin 17A (IL-17A) that binds&#xD;
      with high affinity and with a potency corresponding to clinically tested monoclonal&#xD;
      antibodies in terms of blocking the biological activity of IL-17A. ABY-035 has the potential&#xD;
      to be an efficacious treatment for a variety of IL-17A-related diseases, including psoriasis&#xD;
      and psoriatic arthritis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR50</measure>
    <time_frame>16 weeks</time_frame>
    <description>ACR50 response rate at Week 16</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>ABY-035 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg ABY-035 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABY-035 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg ABY-035 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, switching to 80 mg ABY-035 after 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ABY-035</intervention_name>
    <description>ABY-035 solution for injection</description>
    <arm_group_label>ABY-035 40 mg</arm_group_label>
    <arm_group_label>ABY-035 80 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to ABY-035 solution for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient who has given his / her signed declaration of consent and data protection&#xD;
             declaration&#xD;
&#xD;
          -  At least 18 years and less than 75 years of age at Screening visit&#xD;
&#xD;
          -  Psoriatic arthritis with inflammatory musculoskeletal disease (joint, spine, or&#xD;
             entheseal) with the presence of ≥3 points from the five categories of the&#xD;
             Classification Criteria for Psoriatic Arthritis (CASPAR) at any timepoint in medical&#xD;
             history.&#xD;
&#xD;
          -  Active psoriatic arthritis defined by:&#xD;
&#xD;
          -  ≥3 swollen joints out of 66 joints (SJC66) at Screening visit and Baseline visit&#xD;
&#xD;
          -  ≥3 tender joints out of 68 (TJC68) at Screening visit and Baseline visit&#xD;
&#xD;
          -  Precedent failure or insufficient treatment response to or contraindication or&#xD;
             intolerability to nonsteroidal antiphlogistic drug (NSAID) and / or DMARD&#xD;
&#xD;
          -  Rheumatoid factor (RF) and anti-CCP antibody negative&#xD;
&#xD;
          -  Presence or history of plaque psoriasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying conditions which, significantly immunocompromise the patient and / or place&#xD;
             the patient at unacceptable risk for receiving an immunomodulatory therapy&#xD;
&#xD;
          -  History of or current relevant autoimmune diseases (e.g. rheumatoid arthritis, primary&#xD;
             ankylosing spondylitis, systemic lupus erythematosus) other than psoriasis or&#xD;
             psoriatic arthritis&#xD;
&#xD;
          -  History of or current fibromyalgia or pain syndrome&#xD;
&#xD;
          -  Uncontrolled inflammatory bowel disease&#xD;
&#xD;
          -  Presence or history of recurrent or medically important infections in the last 6&#xD;
             months prior to Baseline visit&#xD;
&#xD;
          -  Clinically relevant Candida infection requiring systemic treatment within the last 6&#xD;
             months prior to Baseline visit&#xD;
&#xD;
          -  History or any signs of lymphoproliferative disease, or a known malignancy or a&#xD;
             history of malignancy within the previous 5 years&#xD;
&#xD;
          -  Insufficiently controlled heart failure&#xD;
&#xD;
          -  Current uncontrolled arterial hyper- or hypotension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Behrens</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affibody</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>rolf westerberg</last_name>
    <phone>+46705415413</phone>
    <email>rolf.westerberg@affibody.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centrum für innovative Diagnostik und Therapie Rheumatologie / Immunologie (CIRI GmbH)</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Behrens</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

